Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
Theriva Biologics, Inc., a Nevada corporation, filed this Current Report on Form 8-K on August 11, 2026. The filing serves to disclose the issuance of a press release containing financial information for the quarter ended June 30, 2026. The company is listed on the NYSE American under the symbol TOVX and is classified as an emerging growth company.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that such data is available in a separate press release (Exhibit 99.1) but does not reproduce the figures within the 8-K text itself.
Material Changes
No material changes versus prior periods are detailed in this filing text. The report references the attached press release for operational and financial updates but does not summarize comparative performance metrics.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings. No specific guidance, outlook, or risk factors are articulated in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 11, 2026) for actual financial figures for the quarter ended June 30, 2026.
- Verify the company's cash position and runway given the lack of specific liquidity data in this summary filing.
- Confirm the status of the company's emerging growth company election and any related accounting standard transitions.
- Check for any subsequent filings that may incorporate the press release data by reference.